Everything below concerns prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
=== Copolymers === The copolymer Poly(vinylidene fluoride-co-hexafluoropropylene) or PVDF-HFP is used as a co-polymer in the blades of artificial turf. Addition of organoclay to PVDF-HFP via melt compounding stabilizes the β piezoelectric phase. Copolymers of PVDF are also used in piezoelectric and electrostrictive applications. One of the most commonly used copolymers is P(VDF-trifluoroethylene), usually available in ratios of about 50:50 and 65:35 by mass (equivalent to about 56:44 and 70:30 molar fractions). Another one is P(VDF-tetrafluoroethylene). They improve the piezoelectric response by improving the crystallinity of the material. While the copolymers' unit structures are less polar than that of pure PVDF, the copolymers typically have a much higher crystallinity. This results in a larger piezoelectric response: d33 values for P(VDF-TFE) have been recorded to be as high as −38 p C/N compared to −33 pC/N in pure PVDF.
According to limerence theory, posited in 1979 by psychologist Dorothy Tennov, a certain percentage of couples may go through what is called a limerent reaction, in which one or both of the pair may experience a state of passion mixed with continuous intrusive thinking, fear of rejection, and hope. Hence, with all human romantic relationships, one of three varieties of bonds may form, defined over a set duration of time, in relation to the experience or non-experience of limerence:
==== Detecting trojans ==== Machine learning models can potentially contain "trojans" or "backdoors": vulnerabilities that bad actors maliciously build into an AI system. For example, a trojaned facial recognition system could grant access when a specific piece of jewelry is in view; or a trojaned autonomous vehicle may function normally until a specific trigger is visible. This might not be difficult to do with some large models like CLIP or GPT-3 as they are trained on publicly available internet data. Researchers were able to plant a trojan in an image classifier by changing just 300 out of 3 million of the training images. In addition to posing a security risk, researchers have argued that trojans provide a concrete setting for testing and developing better monitoring tools. A 2024 research paper by Anthropic showed that large language models could be trained with persistent backdoors. These "sleeper agent" models could be programmed to generate malicious outputs (such as vulnerable code) after a specific date, while behaving normally beforehand. Standard AI safety measures, such as supervised fine-tuning, reinforcement learning and adversarial training, failed to remove these backdoors.
Two days after the execution, then-Governor Jeb Bush suspended all executions in the state and appointed a commission "to consider the humanity and constitutionality of lethal injections." The ban was lifted by Governor Charlie Crist when he signed the death warrant for Mark Dean Schwab on July 18, 2007. On November 1, 2007, the Florida Supreme Court unanimously upheld the state's lethal-injection procedures. A study published in 2007 in PLOS Medicine suggested that "the conventional view of lethal injection leading to an invariably peaceful and painless death is questionable." The execution of Romell Broom was abandoned in Ohio on September 15, 2009, after prison officials failed to find a vein after two hours of trying on his arms, legs, hands, and ankle. This stirred up more intense debate in the United States about lethal injection. Broom's execution was later rescheduled for March 2022, but he died in 2020 before the sentence could be carried out. Dennis McGuire was executed in Lucasville, Ohio, on January 17, 2014. According to reporters, McGuire's execution took more than 20 minutes, and he was gasping for air for 10–13 minutes after the drugs had been administered. It was the first use of a new drug combination, which was introduced in Ohio after the European Union banned sodium thiopental exports. This reignited criticism of the conventional three-drug method. Clayton Lockett died of a heart attack during a failed execution attempt on April 29, 2014, at Oklahoma State Penitentiary in McAlester, Oklahoma.
Sources: en.wikipedia.org
The second-generation NSAAs enzalutamide and apalutamide were derived from and are analogues of the first-generation NSAAs, while another second-generation NSAA, darolutamide, is said to be structurally distinct and chemically unrelated to the other NSAAs. Enzalutamide is a modification of bicalutamide in which the inter-ring linking chain has been altered and cyclized into a 5,5-dimethyl-4-oxo-2-thioxo imidazolidine moiety. In apalutamide, the 5,5-dimethyl groups of the imidazolidine ring of enzalutamide are cyclized to form an accessory cyclobutane ring and one of its phenyl rings is replaced with a pyridine ring.
==== Feud with outgoing Vice President Verónica Abad Rojas ==== Upon their inauguration in November 2023, both Noboa and Abad Rojas distanced themselves from each other, with Abad Rojas launching personal attacks against Noboa. She did not appear in the inaugural photo of the cabinet and subsequently was appointed ambassador to Israel. Shortly thereafter, she was ordered to move to Istanbul within three days. Abad Rojas called these decisions a "forced exile". In June 2024, Abad Rojas survived an impeachment attempt by the Noboa government due to legal issues. In November 2024, she was suspended from the vice presidency by the labor ministry for 150 days. Noboa named Secretary of National Planning Sariha Moya as acting vice president. Abad Rojas' suspension was lifted by a judge in December 2024, along with an order for the labor ministry to give her an apology for the suspension. According to Ecuador's electoral law, the president is required to take a leave of absence during the presidential campaign and appoint the elected vice-president to act as president temporarily. Noboa refused to appoint Abad Rojas as interim president during the election campaign. Instead, in January 2025, he appointed Cynthia Gellibert as vice president with temporary presidential responsibilities during the campaign. On 30 March 2025, Noboa caused controversy for ignoring the Constitutional Court and appointing Cynthia Gellibert by decree as vice president, suspending Abad Rojas once again.
The dressing is applied to a cleaned wound, and usually used to treat uninfected wounds. The dressings may be used, under medical supervision and with an antibiotic to treat the infection, even where aerobic bacterial infection is present. In addition to treating abrasions, minor incisions and lacerations, and superficial puncture wounds, hydrocolloid dressings are used to cover skin-graft donor sites, burns, and cutaneous ulcers (including pressure ulcers or "bed sores", venous ulcers, and diabetic foot ulcers). Small hydrocolloid patches are sometimes also used for acne, to heal the pimples and avoid scars from them. Large dressings with a consistent, adhesive film across the active side (rather than a central pad of hydrocolloid foam) can be cut into smaller strips or other shapes, for use in place of a traditional adhesive bandage of the same size. An indirectly medical use of strips of hydrocolloid dressing is as an alternative to surgical tape, e.g. to secure a nasogastric tube or CPAP mask to a patient's face.
Crabby Joe's is a restaurant and bar chain founded in 1996 with 15 Ontario locations and headquarters in Mississauga. "Obsidian Group Inc." has made the decision to swap some of their Crabby Joe's restaurants to "Chuck's Roadhouse". In 2025, the chain had 15 locations across southern Ontario.
While only some 6.4% of forests inside of legally declared protected areas were cleared between 1980 and 2010, over a quarter of forests outside of protected areas were lost between 1980 and 2010. As a country with a relatively high forest cover and a low deforestation rate, Belize has significant potential for participation in initiatives such as REDD. Significantly, the SERVIR study on Belize's deforestation was also recognized by the Group on Earth Observations (GEO), of which Belize is a member nation.
Sources: en.wikipedia.org
== History == CTS was first described around 1850 but was infrequently diagnosed until findings were publicized by neurologist W. Russell Brain in 1947. People were often diagnosed with acroparesthesia. Clinicians would often ascribe it to "poor circulation" and not pursue it further. Sir James Paget described median nerve compression at the carpal tunnel in two patients after trauma in 1854. The first was due to an injury where a cord had been wrapped around a man's wrist. The second was related to a distal radial fracture. For the first case, Paget performed an amputation of the hand. For the second case, Paget recommended a wrist splint. The first to notice the association between the carpal ligament pathology and median nerve compression appears to have been Pierre Marie and Charles Foix in 1913. They described the results of a postmortem of an 80-year-old man with bilateral carpal tunnel syndrome. They suggested that division of the carpal ligament would be curative in such cases. Putman had previously described a series of 37 patients and suggested a vasomotor origin. The association between the thenar muscle atrophy and compression was noted in 1914. The name "carpal tunnel syndrome" appears to have been coined by Moersch in 1938. Physician George S. Phalen of the Cleveland Clinic drew attention to the pathology of compression as the reason for CTS after working with a group of patients in the 1950s and 1960s.
RCO2H + R'2NH → RCO−2 + R'2NH+2 RCO−2 + R'2NH+2 → RC(O)NR'2 + H2O Esters are far superior substrates relative to carboxylic acids. Further "activating" both acid chlorides (Schotten-Baumann reaction) and anhydrides (Lumière–Barbier method) react with amines to give amides:
Traumatic: Traumatic breaks in Descemet membrane may cause corneal opacity. Injuries to Descemet membrane occur during delivery. Opacity is commonly unilateral. Congenital or infantile glaucoma: In Congenital glaucoma, the cornea becomes edematous, cloudy, and enlarged. Treatment should be done to reduce Intraocular pressure. Congenital corneal ulcers: Unilateral corneal opacity may occur in association with conjunctival injection and other signs of inflammation. Mucopolysaccharidoses: The mucopolysaccharidoses are a group of inherited metabolic diseases caused by the absence or malfunctioning of certain enzymes the body needs to break down molecules called glycosaminoglycans. It is an autosomal recessive disorder. Sometimes, Corneal haze may be present in early life. Treatment options for significant opacities include penetrating keratoplasty and DALK.
=== Bulimia nervosa === A 2011 systematic review discussed seven trials that compared fluoxetine to a placebo in the treatment of bulimia nervosa, six of which found a statistically significant reduction in symptoms such as vomiting and binge eating. However, no difference was observed between treatment arms when fluoxetine and psychotherapy were compared to psychotherapy alone.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.